Antidepressant Investigations Continue; GAO Studying FDA Process
Executive Summary
The Government Accountability Office is studying how FDA resolves internal disputes about drug safety issues
You may also be interested in...
“Independent” Drug Safety Office Is Goal Of Senate Vioxx Investigation
The idea of an "independent" drug safety office in FDA merits consideration, Office of New Drugs Acting Director Sandra Kweder, MD, said during the Senate Finance Committee hearing Nov. 18 on Merck's withdrawal of Vioxx
“Independent” Drug Safety Office Is Goal Of Senate Vioxx Investigation
The idea of an "independent" drug safety office in FDA merits consideration, Office of New Drugs Acting Director Sandra Kweder, MD, said during the Senate Finance Committee hearing Nov. 18 on Merck's withdrawal of Vioxx
Clinical Trial Disclosure Legislation Likely To Await PhRMA, AMA Discussions
The next step in the push to create a national database of clinical trial results is likely to be discussion among stakeholders rather than legislation